It is possible that the mutant rootletin either has a dominant phenotype (e.g. in delaying resolution of centrosome cohesion at mitotic onset or CROCC mutations may work synergistically together with other mutations in colorectal cancer). This evidence concerns the gene CROCC and colorectal cancer.